Methods and rationale of the DISCOVER CKD global observational study

• Published in: Clinical Kidney Journal 2021-06, Vol.14 (6), p.1570-1578
• Main Authors: Pecoits-Filho, Roberto, James, Glen, Carrero, Juan Jesus, Wittbrodt, Eric, Fishbane, Steven, Sultan, Alyshah Abdul, Heerspink, Hiddo J L, Hedman, Katarina, Kanda, Eiichiro, Chen, Hungta (Tony), Kashihara, Naoki, Sloand, James, Kosiborod, Mikhail, Kumar, Supriya, Lainscak, Mitja, Arnold, Matthew, Lam, Carolyn S P, Holmqvist, Björn, Pollock, Carol, Fenici, Peter, Stenvinkel, Peter, Medin, Jennie, Wheeler, David C
• Format: Article
• Language: English
• Subjects: Analysis; Chronic kidney failure; Epidemiology; Exercise; Food habits; Medicin och hälsovetenskap; Methods; Original; Pharmaceutical industry
• ISSN: 2048-8505; 2048-8513
• DOI: 10.1093/ckj/sfab046

Abstract Background Real-world data for patients with chronic kidney disease (CKD), specifically pertaining to clinical management, metabolic control, treatment patterns, quality of life (QoL) and dietary patterns, are limited. Understanding these gaps using real-world, routine care data will improve our understanding of the challenges and consequences faced by patients with CKD, and will facilitate the long-term goal of improving their management and prognosis. Methods DISCOVER CKD follows an enriched hybrid study design, with both retrospective and prospective patient cohorts, integrating primary and secondary data from patients with CKD from China, Italy, Japan, Sweden, the UK and the USA. Data will be prospectively captured over a 3-year period from >1000 patients with CKD who will be followed up for at least 1 year via electronic case report form entry during routine clinical visits and also via a mobile/tablet-based application, enabling the capture of patient-reported outcomes (PROs). In-depth interviews will be conducted in a subset of ∼100 patients. Separately, secondary data will be retrospectively captured from >2 000 000 patients with CKD, extracted from existing datasets and registries. Results The DISCOVER CKD program captures and will report on patient demographics, biomarker and laboratory measurements, medical histories, clinical outcomes, healthcare resource utilization, medications, dietary patterns, physical activity and PROs (including QoL and qualitative interviews). Conclusions The DISCOVER CKD program will provide contemporary real-world insight to inform clinical practice and improve our understanding of the epidemiology and clinical and economic burden of CKD, as well as determinants of clinical outcomes and PROs from a range of geographical regions in a real-world CKD setting.